The authors of a new study argue that an add-on to improve traditional prostate-specific antigen (PSA) screening for prostate cancer provides minimal benefit in identifying those cancers that are truly life threatening and should not be recommended in practice guidelines. But other experts reject this controversial opinion.
PSA screening remains a less-than-ideal method for detecting deadly prostate cancer, and researchers have tried to improve its specificity by adding other variables, such as race or family history, or different measures of PSA level, such as free PSA and
Mitka M. Experts Debate Utility of PSA Velocity as a Criterion for Prostate Biopsy. JAMA. 2011;305(15):1522. doi:10.1001/jama.2011.492
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: